Benzthiazide NEW
| Price | $39 |
| Package | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2026-02-03 |
Product Details
| Product Name: Benzthiazide | CAS No.: 91-33-8 |
| Purity: 99.77% | Supply Ability: 10g |
| Release date: 2026/02/03 |
Product Introduction
Bioactivity
| Name | Benzthiazide |
| Description | Benzthiazide (Lemazide) is used in the therapy of edema and hypertension. Like other thiazides, benzthiazide accelerates water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (115.76 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.63 mM), Sonication is recommended. |
| Keywords | Inhibitor | inhibit | CarbonicAnhydrase | Carbonic anhydrase | Carbonate dehydratase | Benzthiazide |
| Inhibitors Related | Benzenesulfonamide | Urea | Sodium Dihydrogen Phosphate | Cyclamic acid sodium | Hydrochlorothiazide | Orthanilamide | Zonisamide | Tioxolone | 2-Methoxy-4-propylphenol | pNNP | Pyrocatechol | Acesulfame |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $39.00/100mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-02-03 | |
| $39.00/100mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-04-30 | |
| $1.00/1g |
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-05-08 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY